PEG-Lipid Polymer Compounds for Targeted mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid delivery methods, particularly for mRNA therapy, face challenges such as low efficiency, high toxicity, and frequent administration requirements, which limit their effectiveness in treating various diseases.
Innovation Solution
The development of polymers with organic polymeric segments covalently attached to two or more lipid substructures, which can be used to create liposomes for targeted mRNA delivery. These polymers include segments like polyethylene glycol (PEG) and lipid substructures such as ceramide, glycerolipid, sterol, and phospholipid, enhancing delivery efficiency and reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current nucleic acid delivery methods are used, then mRNA therapy can be administered, but delivery efficiency is low and administration frequency is high
Solution Approach 1:
The patent uses composite lipid-polymer structures where PEGylated lipids are incorporated into liposomal delivery systems. This composite material approach combines the benefits of lipids (biocompatibility) with PEG polymers (prolonged circulation, reduced immunogenicity), achieving both high delivery efficiency and reduced administration frequency through enhanced cellular uptake and sustained release properties
2Object-affected harmful factors
If current nucleic acid delivery methods are used, then mRNA therapy can be delivered, but toxicity is high
Solution Approach 1:
The patent modifies the chemical parameters of the delivery system by incorporating PEGylated lipids with specific chain lengths and densities. This parameter optimization reduces the immunogenicity and cytotoxicity of the liposomal system while maintaining effective mRNA delivery, thereby improving patient tolerability and reliability of the therapy
3Manufacturing precision
If PEG polymers are attached to lipid substructures, then targeted delivery is improved, but polymer structure complexity increases
Solution Approach 1:
The patent divides the complex PEG-lipid conjugate into modular segments: a lipid anchor portion that integrates into the liposomal membrane, a PEG spacer chain providing steric stabilization, and optionally a targeting ligand. This segmentation allows systematic optimization of each component's function while simplifying the overall design and manufacturing process through standardized modular assembly
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed polymer-based liposomes improve the targeted delivery of mRNA, reducing administration frequency, enhancing patient tolerability, and providing a less toxic and more potent mRNA therapy for treating a wide range of diseases, including cancer, cardiovascular diseases, cystic fibrosis, infectious diseases, and neurological disorders.
Implementation Method 1
each lipid substructure independently comprises a hydrophobic moiety and a hydrophilic moiety
Implementation Method 2
an organic polymeric segment comprises covalent attachments to two or more lipid substructures and each lipid substructure independently comprises a hydrophobic moiety and a hydrophilic moiety
Data Source
AI summary
The compounds disclosed herein (e.g., compounds having a structure according to Formula (I), (II), (III), (IV), and (V)) are polymers wherein an organic polymeric segment (e.g., a polyethylene glycol (PEG) group) comprises covalent attachments to two or more lipid substructures, and each lipid substructure independently comprises a hydrophobic moiety and a hydrophilic moiety. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.